Compared to the model group, long-term liraglutide treatment reduced blood glucose levels and significantly alleviated lipid metabolism disorders. Liraglutide also improved impaired cardiac function. Furthermore, the improvement in cardiac dysfunction was associated with reduced myocardial fibrosis in diabetic hearts, as evidenced by decreased expression of P4hα-1, COL-1, COL-3, MMP-1, and MMP-9. Here, MMP1 is linked to Disorder of lipid metabolism.